GeneSight

Shares of molecular diagnostics company Myriad Genetics, Inc. (NASDAQ: MYGN) were rallying to a nine-month high Thursday on above-average volume. Myriad shares are reacting to a decision by UnitedHealth Group Inc (NYSE: UNH) to cover pharmacogenetic testing with multigene panels, including the...

Molecular diagnostics and personalized medicine company Myriad Genetics, Inc. (NASDAQ: MYGN) announced its fiscal third-quarter financial results Tuesday. What Happened Myriad Genetics reported better-than-expected earnings and raised its full-year 2018 guidance. The company also provided an...

Ladenburg Thalmann upgraded shares of Myriad Genetics, Inc. (NASDAQ: MYGN), premised on valuation, as it views that the sell thesis has largely played out. Q2 Largely In Line Analyst Kevin DeGeeter noted that the company reported second-quarter non-GAAP earnings of $0.26 per share on revenues...

Myriad Genetics, Inc. (NASDAQ: MYGN) is a molecular diagnostic company engaged in the development and marketing of transformative molecular diagnostic tests. The company recently announced a new relationship with ION Solutions, a part of AmerisourceBergen Corp. (NYSE: ABC), to deliver hereditary...